Translational Research in Familial Colorectal Cancer Syndromes

Abstract

Growing knowledge of inherited colorectal cancer syndromes has led to better surveillance and better care of this subset of patients. The most well-known entities, including Lynch syndrome and familial adenomatous polyposis, are continually being studied and with the advent of more sophisticated genetic testing, additional genetic discoveries have been made in the field of inherited cancer. This article will summarize many of the updates to both the familiar and perhaps less familiar syndromes that can lead to inherited or early-onset colorectal cancer.

Keywords

familial colorectal cancer - Lynch syndrome - FAP - serrated polyposis - POLE/POLD1

• References

• 1 Evans JP, Sutton PA, Winiarski BK. , et al. From mice to men: murine models of colorectal cancer for use in translational research. Crit Rev Oncol Hematol 2016; 98: 94-105
• 2 Chubb D, Broderick P, Frampton M. , et al. Genetic diagnosis of high-penetrance susceptibility for colorectal cancer (CRC) is achievable for a high proportion of familial CRC by exome sequencing. J Clin Oncol 2015; 33 (05) 426-432
• 3 Laboratores MG. Myriad myRisk Hereditary Cancer Technical Specifications. Available at: https://s3.amazonaws.com/myriad-library/technical-specifications/myRisk+Hereditary+Cancer+Tech+Specs.pdf . Accessed March 24, 2016
• 4 Heinen CD. Mismatch repair defects and Lynch syndrome: the role of the basic scientist in the battle against cancer. DNA Repair (Amst) 2016; 38: 127-134
• 5 Carethers JM, Stoffel EM. Lynch syndrome and Lynch syndrome mimics: the growing complex landscape of hereditary colon cancer. World J Gastroenterol 2015; 21 (31) 9253-9261
• 6 Network NCC. Genetic/Familial High-Risk Assessment: Colorectal. Available at http://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf . Accessed February 22, 2016
• 7 Sargent DJ, Shi Q, Yothers G. , et al. Prognostic impact of deficient mismatch repair (dMMR) in 7,803 stage II/III colon cancer (CC) patients (pts): a pooled individual pt data analysis of 17 adjuvant trials in the ACCENT database. J Clin Oncol 2014; 32 (15, Suppl): 3507 [Meeting Abstracts]
• 8 Ribic CM, Sargent DJ, Moore MJ. , et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349 (03) 247-257
• 9 Sargent DJ, Marsoni S, Monges G. , et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010; 28 (20) 3219-3226
• 10 Sinicrope FA, Foster NR, Thibodeau SN. , et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst 2011; 103 (11) 863-875
• 11 Fink D, Nebel S, Aebi S. , et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996; 56 (21) 4881-4886
• 12 Zaanan A, Gauthier M, Malka D. , et al; Association des Gastro Entérologues Oncologues. Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: a multicenter AGEO study. Cancer 2011; 117 (07) 1422-1428
• 13 André T, de Gramont A, Vernerey D. , et al. Adjuvant fluorouracil, leucovorin, and oxaliplatin in Stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. J Clin Oncol 2015; 33 (35) 4176-4187
• 14 Gavin PG, Colangelo LH, Fumagalli D. , et al. Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res 2012; 18 (23) 6531-6541
• 15 Kawakami H, Zaanan A, Sinicrope FA. Implications of mismatch repair-deficient status on management of early stage colorectal cancer. J Gastrointest Oncol 2015; 6 (06) 676-684
• 16 Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 1988; 48 (15) 4399-4404
• 17 Burn J, Mathers J, Bishop DT. Lynch syndrome: history, causes, diagnosis, treatment and prevention (CAPP2 trial). Dig Dis 2012; 30 (Suppl. 02) 39-47
• 18 Ait Ouakrim D, Dashti SG, Chau R. , et al. Aspirin, ibuprofen, and the risk of colorectal cancer in Lynch syndrome. J Natl Cancer Inst 2015; 107 (09) djv385
• 19 Giardiello FM, Allen JI, Axilbund JE. , et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer. Dis Colon Rectum 2014; 57 (08) 1025-1048
• 20 Rodríguez-Soler M, Pérez-Carbonell L, Guarinos C. , et al. Risk of cancer in cases of suspected lynch syndrome without germline mutation. Gastroenterology 2013; 144 (05) 926-932.e1 , quiz e13–e14
• 21 Lindor NM, Rabe K, Petersen GM. , et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 2005; 293 (16) 1979-1985
• 22 Bakry D, Aronson M, Durno C. , et al. Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: report from the constitutional mismatch repair deficiency consortium. Eur J Cancer 2014; 50 (05) 987-996
• 23 Sijmons RH, Hofstra RM. Review: clinical aspects of hereditary DNA mismatch repair gene mutations. DNA Repair (Amst) 2016; 38: 155-162
• 24 Herkert JC, Niessen RC, Olderode-Berends MJ. , et al. Paediatric intestinal cancer and polyposis due to bi-allelic PMS2 mutations: case series, review and follow-up guidelines. Eur J Cancer 2011; 47 (07) 965-982
• 25 Vasen HF, Ghorbanoghli Z, Bourdeaut F. , et al; EU-Consortium Care for CMMR-D (C4CMMR-D). Guidelines for surveillance of individuals with constitutional mismatch repair-deficiency proposed by the European Consortium “Care for CMMR-D” (C4CMMR-D). J Med Genet 2014; 51 (05) 283-293
• 26 Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW. ; American College of Gastroenterology. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 2015; 110 (02) 223-262 , quiz 263
• 27 Kim B, Giardiello FM. Chemoprevention in familial adenomatous polyposis. Best Pract Res Clin Gastroenterol 2011; 25 (4-5): 607-622
• 28 Burn J, Bishop DT, Chapman PD. , et al; International CAPP consortium. A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res (Phila) 2011; 4 (05) 655-665
• 29 Steinbach G, Lynch PM, Phillips RK. , et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342 (26) 1946-1952
• 30 Taupin D, Lam W, Rangiah D. , et al. A deleterious RNF43 germline mutation in a severely affected serrated polyposis kindred. Hum Genome Var 2015; 2: 15013
• 31 Gala MK, Mizukami Y, Le LP. , et al. Germline mutations in oncogene-induced senescence pathways are associated with multiple sessile serrated adenomas. Gastroenterology 2014; 146 (02) 520-529
• 32 East JE, Vieth M, Rex DK. Serrated lesions in colorectal cancer screening: detection, resection, pathology and surveillance. Gut 2015; 64 (06) 991-1000
• 33 Jspeert JE, Rana SA, Atkinson NS. , et al. Dutch workgroup serrated polyps & polyposis (WASP). Clinical risk factors of colorectal cancer in patients with serrated polyposis syndrome: a multicentre cohort analysis. Gut 2017; 66 (02) 278-284
• 34 Palles C, Cazier JB, Howarth KM. , et al; CORGI Consortium; WGS500 Consortium. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet 2013; 45 (02) 136-144 “Palles, Cazier, Howarth, et al, 2013” was corrected in “Nat Genet. 2013 Jun;45(6):713” (Note: Guarino Almeida, Estrella [corrected to Guarino, Estrella])
• 35 Bellido F, Pineda M, Aiza G. , et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med 2016; 18 (04) 325-332
• 36 Goldvaser H, Purim O, Kundel Y. , et al. Colorectal cancer in young patients: is it a distinct clinical entity?. Int J Clin Oncol 2016; 21 (04) 684-695
• 37 Abdelsattar ZM, Wong SL, Regenbogen SE, Jomaa DM, Hardiman KM, Hendren S. Colorectal cancer outcomes and treatment patterns in patients too young for average-risk screening. Cancer 2016; 122 (06) 929-934
• 38 Siegel RL, Jemal A, Ward EM. Increase in incidence of colorectal cancer among young men and women in the United States. Cancer Epidemiol Biomarkers Prev 2009; 18 (06) 1695-1698
• 39 Ballester V, Rashtak S, Boardman L. Clinical and molecular features of young-onset colorectal cancer. World J Gastroenterol 2016; 22 (05) 1736-1744